Home  »  Companies   »  Are we looking at the next big move in Phio Pharma...

Are we looking at the next big move in Phio Pharmaceuticals Corp. (PHIO)?

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is -9.67% lower on its value in year-to-date trading and has touched a low of $1.76 and a high of $6.48 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The PHIO stock was last observed hovering at around $2.37 in the last trading session, with the day’s gains setting it 0.06% off its average median price target of $4.00 for the next 12 months. It is also 39.25% off the consensus price target high of $4.00 offered by 1 analysts, but current levels are 39.25% higher than the price target low of $4.00 for the same period.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Currently trading at $2.43, the stock is -2.47% and -14.50% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.43 million and changing 2.53% at the moment leaves the stock -5.92% off its SMA200. PHIO registered 33.88% gain for a year compared to 6-month gain of 17.96%. The firm has a 50-day simple moving average (SMA 50) of $2.6726 and a 200-day simple moving average (SMA200) of $2.6951.

The stock witnessed a -6.18% loss in the last 1 month and extending the period to 3 months gives it a -20.59%, and is 3.40% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.91% over the week and 6.90% over the month.

Distance from 52-week low is 38.07% and -62.50% from its 52-week high.

Phio Pharmaceuticals Corp. (PHIO) Analyst Forecasts

Analyst recommendations provided by FactSet shows that the consensus forecast for Phio Pharmaceuticals Corp. (PHIO) is a “Buy”. 1 analysts offering their recommendations for the stock, where 0 rate it as a Hold and 0 think it is a “Overweight”. 1 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.

Phio Pharmaceuticals Corp. is expected to release its quarterly report on 08/17/2021 and quarterly earnings per share for the current quarter are estimated at $0.The EPS is expected to grow by 90.10% this year.

Phio Pharmaceuticals Corp. (PHIO) Top Institutional Holders

17 institutions hold shares in Phio Pharmaceuticals Corp. (PHIO), with 165.36k shares held by insiders accounting for 1.22% while institutional investors hold 8.84% of the company’s shares. The shares outstanding are 13.53M, and float is at 13.49M with Short Float at 4.66%. Institutions hold 8.73% of the Float.

The top institutional shareholder in the company is Gsa Capital Partners Llp with over 0.1 million shares valued at $0.27 million. The investor’s holdings represent 0.75% of the PHIO Shares outstanding. As of Dec 30, 2020, the second largest holder is Vanguard Group, Inc. (The) with 73490.0 shares valued at $0.2 million to account for 0.54% of the shares outstanding. The other top investors are Two Sigma Advisers, LP which holds 67700.0 shares representing 0.50% and valued at over $0.18 million, while Dimensional Fund Advisors LP holds 0.19% of the shares totaling 25177.0 with a market value of $67726.0.

Phio Pharmaceuticals Corp. (PHIO) Insider Activity

A total of 0 insider transactions have happened at Phio Pharmaceuticals Corp. (PHIO) in the last six months, with sales accounting for 0 and purchases happening 0 times. The most recent transaction is an insider purchase by Dispersyn Gerrit, the company’s President & CEO. SEC filings show that Dispersyn Gerrit bought 1,953 shares of the company’s common stock on Mar 04 at a price of $2.56 per share for a total of $5000.0. Following the purchase, the insider now owns 89281.0 shares.

Phio Pharmaceuticals Corp. disclosed in a document filed with the SEC on Mar 03 that Ferrara Robert L (Director) bought a total of 682 shares of the company’s common stock. The trade occurred on Mar 03 and was made at $3.15 per share for $2148.0. Following the transaction, the insider now directly holds 13000.0 shares of the PHIO stock.

Still, SEC filings show that on Mar 03, Dispersyn Gerrit (President & CEO) acquired 2,500 shares at an average price of $3.03 for $7575.0. The insider now directly holds 87,328 shares of Phio Pharmaceuticals Corp. (PHIO).

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Related Posts

VNUE Makes Good Progress

VNUE Inc (VNUE) closed the last session almost stable at $0.0112 after seeing a rise of just 1.82% that brought its market cap to $15.81M.

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

7 GROWTH STOCKS FOR 2021

Download Free eBook For

100% free. stop anytime no spam